|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We describe a contiguous gene deletion of the ATM locus in a multi-generation family of Italian descent with a strong family history of pancreatic cancer.
|
31671381 |
2020 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed in vitro experiments using a total of ten human PC cell lines to evaluate anti-tumor effect of AZD1775 (WEE1 inhibitor) alone or combination with AZD0156 (ATM inhibitor).
|
31291716 |
2020 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Further analysis of pancreatic cancer gene chip found OCIAD1 high expression was associating with low ATM expression.
|
31221523 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Zhang and colleagues demonstrate that inhibiting DNA repair by pharmacologic blockade or siRNA silencing of ataxia telangiectasia mutated (ATM) increases type I IFN release via a cGAS/STING-independent, SRC-dependent mechanism in models of pancreatic cancer.
|
31371279 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that pancreatic cancers in patients with germline ATM pathogenic variants are more frequently of colloid (mucinous non-cystic) morphology but are overall morphologically diverse supporting the utility of universal germline genetic testing for patients with pancreatic cancer.
|
31285527 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: This study demonstrates that ATM inhibition induces a T1IFN-mediated innate immune response in pancreatic cancer that is further enhanced by radiation and leads to increased sensitivity to anti-PD-L1 therapy.<i>See related commentary by Gutiontov and Weichselbaum, p. 3815</i>.
|
31101760 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05).
|
29922827 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, the <i>in vitro</i> data confirmed that down-expression of PARP-1 suppressed cell proliferation and induced apoptosis of pancreatic cancer via ATM-deficient p53 signaling pathway.
|
29434894 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results Thirty-three (3.9%; 95% CI, 3.0% to 5.8%) of 854 patients with pancreatic cancer had a deleterious germline mutation, 31 (3.5%) of which affected known familial pancreatic cancer susceptibility genes: BRCA2 (12 patients), ATM (10 patients), BRCA1 (3 patients), PALB2 (2 patients), MLH1 (2 patients), CDKN2A (1 patient), and TP53 (1 patient).
|
28767289 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer.
|
28894253 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pancreatic cancer ATM status may help predict response to radiotherapy.
|
28453388 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest an intimate link between ATM expression and pancreatic cancer progression in mice and men.
|
26220524 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
Loss-of-function variants in ATM confer risk of gastric cancer.
|
26098866 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.
|
26098869 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumoral loss of ATM protein was detected more often in patients with a family history of pancreatic cancer than in those without.
|
24486587 |
2014 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To date, epidemiological studies have assessed the association between Ataxia-telangiectasia mutated (ATM) gene polymorphisms and cancer risk, including lung cancer, breast cancer, glioma and pancreatic cancer.
|
22203481 |
2012 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A statistically significant interaction of ATM D1853N and LIG4 C54T genotype with diabetes on the risk of pancreatic cancer was also detected.
|
19147782 |
2009 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.
|
16520463 |
2006 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Other hereditary disorders predisposing to PC include Peutz-Jeghers syndrome, due to the STK11 mutation, familial pancreatitis due to the cationic trypsinogen gene, site-specific familial pancreatic cancer which may be due to the 4q32-34 mutation, hereditary breast-ovarian cancer (HBOC) syndrome that is due to BRCA2 and possibly some families with HBOC that is due to BRCA1 , familial adenomatous polyposis due to the ATP gene, and ataxia telangiectasia due to the ATM germline mutation.
|
15516847 |
2004 |